With Boeing, that is a distinct possibility.

Bought at the lowest bid? Gus Grissom had something to say about that.

Yep, we got lucky in the timing here, not just the effectiveness of the mRNA vaccines at reducing the effects. If Delta had shown up even just a few months earlier, it would been far, far worse.

The vaccines and their trial data as presented by the pharmaceutical companies made the claim that both mRNA vaccines had a 95% of preventing infection and that is most definitely a lie. (I’m going to ignore that no one in the 75+ age cohort received it, that handful that were included only in the placebo group.) Statistically, only 3.5% of the admissions should be SARS-CoV-2 positive while already vaccinated. (We can ignore variance due to the huge sample size.) What you are advocating is that the vaccines are mitigating the expression of the virus in vaccinated individuals. First off I agree, all the datasets are demonstrating this, everywhere. However, before you pat yourself on the back, not a single trial for any of the vaccines tested for this. None. We just got lucky, thankfully.By the way, I wouldn’t be at all surprised to find out that this is the reason behind the price jump for both mRNA vaccines.

Despite reaching the herd immunity goal of 70% of the population, SARS-CoV-2 is spreading unchecked by the vaccines. 75% of the known new cases are people fully vaccinated. Those are hard facts from the CDC&P. What we have found is that the vaccines are ineffective at stopping the Delta mutation. Further, the transmission rate between individuals vaccinated or not is the same (no statistical difference). From some of the Israeli data, even a booster fails to stop the spread of Delta. Calling the vaccines ineffective is too harsh a conclusion, at the least with Delta. Frankly I barely have a clue who Greene is or her politics. I do know the conclusions above have nothing to do with her. These are conclusions by myself and those in the fields of epidemiology and immunology. Epidemiology is one of my fields both in the lab and out.

More like using their customers for beta-testing, just as with every other shop it seems these days.

And obscure commands and options to those commands that only made sense to the people that wrote the software. Forgot, using octal for flags. Did I mention running on an ancient VAX. ... lots more where those came from. It was rough!

That's my need as well. Tons of accelerators, lots of licences, can't afford the various VDI taxes lurking out there. Intentionally. Buying Server 2008, 2012, or 2012 R2 licenses to get a VDI going is absolutely bonkers. Retail Windows 7 is cheaper for small shops. And if whatever comes out the sausage factory Windows 10 Enterprise might be retail worthy if the damn licenses make sense. It will be ever thus as Microsoft's mindset is extracting the most fees ala Oracle versus helping SO/HO and SMBs. Either accept subscriptions or just go away.

You've dead-on nailed that. When you don't "feed the trolls," you usually end up with fewer of them vying for attention. They never totally disappear unless a lot more people [about five percent] carry, and use, weapons. That sorts itself right quick just as criminals start targeting less likely armed people, say tourists, instead. But we aren't allowed to go there. Whatever.

Unless things have been radically relaxed in the last decade, the standard in hard sciences and medicine remains a 99% confidence interval. It's the social sciences that allow for a 95% confidence interval. Having worked in all the different schools out there, I think I have some confidence in my assertion.

Isn't this what is promised by OpenStack k basically autonomous systems using Puppet, Chef, PowerShell scripts?

Which is why I call Amazon delivery drones: Skeet, with prizes!

Which is the classic example of the dialectic. Speaking of "old farts," Aristotle definitely qualifies

Foreground, I'll accept. Background is huge whether IE or Chrome on Windows with 32 GB physical and around 67 GB total virtual memory just over 50% utilization.